#long-acting injectables

Some People With HIV Still Experience Treatment Challenges

Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.

Whether for treatment or prevention, women’s interest in injectable antiretrovirals varied based on their relationship with injection.

A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.

COVID-19, HIV vaccines, cure news and long-acting injectables stood out among the top HIV treatment stories of the year.

The European Medicines Agency gave the green light to injectable cabotegravir and rilpivirine for HIV treatment.

A new long-acting injectables HIV drug shows promise in monkey study.

A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.

Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.

After years of taking daily oral cabotegravir and Edurant, people with suppressed HIV switched to long-acting injectable Cabenuva.

A study found no difference in outcomes based on whether participants took oral meds for a month before switching to injectables.

Cabotegravir injections given every eight weeks as PrEP are even more effective than daily Truvada.

The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.

The injectable cabotegravir, given every eight weeks, is just as effective as daily Truvada for HIV prevention.

Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.

A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.